{"id":971018,"date":"2026-06-05T08:04:45","date_gmt":"2026-06-05T12:04:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"modified":"2026-06-05T08:04:45","modified_gmt":"2026-06-05T12:04:45","slug":"collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","title":{"rendered":"Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc.<\/a>\u00a0(Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company’s 2026 Inducement Plan (the 2026 Inducement Plan).<\/p>\n

The Company granted 50,305 restricted stock units (RSUs), in aggregate, as a material inducement to the employment of 34 non-executive individuals newly hired by the Company. Each RSU represents a contingent right to receive one share of the Company\u2019s common stock. One-third of the RSUs shall vest on June 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the employee\u2019s continued service with the Company through each applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company\u2019s common stock.<\/p>\n

The above-described RSUs were granted outside of the Company’s stockholder-approved equity incentive plan pursuant to the 2026 Inducement Plan, which was adopted by the Company’s board of directors (the Board) on May 11, 2026 as a material inducement to the individuals entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n

\n About\u00a0Collegium Pharmaceutical, Inc.<\/strong>
\n
Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold,\u00a0science-backed\u00a0approaches can redefine what treatment looks like in categories too often shaped by complexity\u00a0and\u00a0misconceptions.<\/p>\n

With a\u00a0portfolio of differentiated ADHD medications, anchored by JORNAY PM\u00ae (methylphenidate HCl) and AZSTARYS\u00ae (serdexmethylphenidate\u00a0and dexmethylphenidate), and an established leadership position in responsible pain management, Collegium\u00a0leads\u00a0with the scientific rigor and commercial expertise to deliver treatment options around how\u00a0people live their lives.\u00a0For more information, please visit\u202fcollegiumpharma.com<\/a>\u00a0or\u00a0find us on LinkedIn<\/a>.<\/p>\n

\n Investor Contact:<\/strong>
\n
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc.\u00a0(Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company’s 2026 Inducement Plan (the 2026 Inducement Plan). The Company granted 50,305 restricted stock units (RSUs), in aggregate, as a material inducement to the employment of 34 non-executive individuals newly hired by the Company. Each RSU represents a contingent right to receive one share of the Company\u2019s common stock. One-third of the RSUs shall vest on June 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the employee\u2019s continued service with the Company through each applicable vesting date. The RSUs will be settled on each … <\/p>\n

Continue reading “Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-971018","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCollegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc.\u00a0(Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company’s 2026 Inducement Plan (the 2026 Inducement Plan). The Company granted 50,305 restricted stock units (RSUs), in aggregate, as a material inducement to the employment of 34 non-executive individuals newly hired by the Company. Each RSU represents a contingent right to receive one share of the Company\u2019s common stock. One-third of the RSUs shall vest on June 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the employee\u2019s continued service with the Company through each applicable vesting date. The RSUs will be settled on each … Continue reading "Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T12:04:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTMyNyM3NjM1MDYwIzIwMTg3MjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-06-05T12:04:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\"},\"wordCount\":326,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTMyNyM3NjM1MDYwIzIwMTg3MjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\",\"name\":\"Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTMyNyM3NjM1MDYwIzIwMTg3MjM=\",\"datePublished\":\"2026-06-05T12:04:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTMyNyM3NjM1MDYwIzIwMTg3MjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTczMTMyNyM3NjM1MDYwIzIwMTg3MjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","og_locale":"en_US","og_type":"article","og_title":"Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc.\u00a0(Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company’s 2026 Inducement Plan (the 2026 Inducement Plan). The Company granted 50,305 restricted stock units (RSUs), in aggregate, as a material inducement to the employment of 34 non-executive individuals newly hired by the Company. Each RSU represents a contingent right to receive one share of the Company\u2019s common stock. One-third of the RSUs shall vest on June 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the employee\u2019s continued service with the Company through each applicable vesting date. The RSUs will be settled on each … Continue reading \"Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-05T12:04:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTMyNyM3NjM1MDYwIzIwMTg3MjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-06-05T12:04:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"},"wordCount":326,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTMyNyM3NjM1MDYwIzIwMTg3MjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","name":"Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTMyNyM3NjM1MDYwIzIwMTg3MjM=","datePublished":"2026-06-05T12:04:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTMyNyM3NjM1MDYwIzIwMTg3MjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTczMTMyNyM3NjM1MDYwIzIwMTg3MjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-pharmaceutical-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/971018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=971018"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/971018\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=971018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=971018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=971018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}